Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 18 of 18

List	Outcome	Time frame	Description
Primary	Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS)	Baseline and Week 8	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.
Secondary	Mean change from baseline in the frequency of mild to severe VMS	Baseline and up to Week 12	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.
Secondary	Mean change from baseline in the frequency of moderate to severe VMS	Baseline and up to Week 12	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.
Secondary	Mean percent reduction in the frequency of mild to severe VMS from baseline	Baseline and up to Week 12	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Mean percent reduction will be reported.
Secondary	Mean percent reduction in the frequency of moderate to severe VMS from baseline	Baseline and up to Week 12	Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Mean percent reduction will be reported.
Secondary	Percent reduction of >/= 50% in the frequency of mild to severe VMS from baseline	Baseline and up to Week 12	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of \>/= 50% will be reported.
Secondary	Percent reduction of >/= 75% in the frequency of mild to severe VMS from baseline	Baseline and up to Week 12	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of \>/= 75% will be reported.
Secondary	Percent reduction of 100% in the frequency of mild to severe VMS from baseline	Baseline and up to Week 12	Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of 100% will be reported.
Secondary	Percent reduction of >/= 50% in the frequency of moderate to severe VMS from baseline	Baseline and up to Week 12	Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of \>/= 50% will be reported.
Secondary	Percent reduction of >/= 75% in the frequency of moderate to severe VMS from baseline	Baseline and up to Week 12	Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of \>/= 75% will be reported.
Secondary	Percent reduction of 100% in the frequency of moderate to severe VMS from baseline	Baseline and up to Week 12	Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of 100% will be reported.
Secondary	Number of participants with Adverse Events (AEs)	Up to Week 15	An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.
Secondary	Change from baseline in endometrial thickness	Baseline and up to Week 12	Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).
Secondary	Number of participants with laboratory value abnormalities and/or AEs	Up to Week 15	Number of participants with potentially clinically significant laboratory values.
Secondary	Number of participants with vital sign abnormalities and/or AEs	Up to Week 15	Number of participants with potentially clinically significant vital sign values.
Secondary	Number of participants with electrocardiogram (ECG) abnormalities and/or AEs	Up to Week 12	Number of participants with potentially clinically significant ECG values.
Secondary	Pharmacokinetics (PK) of fezolinetant in plasma: Concentration	Up to Week 12	Concentration will be recorded from the PK plasma samples collected.
Secondary	Pharmacokinetics (PK) of metabolite ES259564 in plasma: Concentration	Up to Week 12	Concentration will be recorded from the PK plasma samples collected.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06206408/registered

API reference For AI assistants